Certain immune cells are linked to a weaker immunotherapy response in melanoma
In samples from six people, these cells often sat next to exhausted immune cells. Whether they themselves blunt treatment is still open.
A study published in Genome Medicine on 3 November 2026 examined why immunotherapy does not work for everyone with melanoma, a form of skin cancer. Immunotherapy is meant to strengthen the body’s own defence against the tumour. The Freiburg team found certain scavenger cells, called lipid-associated macrophages, more often in people whose treatment did not work. In spatially examined samples from six patients, these cells often lay next to T cells that could barely attack cancer cells any more. In people whose treatment worked, other scavenger cells activated by interferon more often lay next to active T cells.
In data from 334 further people, a large number of these lipid-associated scavenger cells was linked to a poorer response and less favourable survival. Their location next to T cells does not prove that the scavenger cells blunt the defence. They may only be a sign of other processes in the tumour. The patterns are not yet a tool for deciding on a treatment.
Sources
- Was Immuntherapien bei Hautkrebs ausbremsen könnte (opens in a new tab) · Deutsches Konsortium für Translationale Krebsforschung (DKTK) · Accessed on